GHRS
GH ResearchCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The constructive view is that GH001 now has peer-reviewed Phase 2b data, the FDA hold has been lifted, and cash was reported at $280.7 million at year-end 2025, giving GHRS a funded shot at moving into a global pivotal program if FDA alignment is achieved [#PR-2026-01-05] [#PR-2026-03-05] [#PR-2026-03-25].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +9.9.
What can break
FDA hold removal helps, but successful FDA alignment on the planned global Phase 3 design is still an unresolved execution gate.
Momentum
92
Value
41
Sentiment
27
Setup hits (3d)
— · Net —
AI TargetsBase $24.00 · Bull $36.00 · Bear $11.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $38.56
Why
Momentum92 · Δ7d +9.9
Value41 · Δ7d -0.1
Sentiment27 · Δ7d -9.3
So what
Balanced signals. Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
92
26% active weight
Current posture
7d trendImproving
Δ7d
+9.9
Δ21d
+11.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
27
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.3
Δ21d
-3.0
Why this grade
Composite grade C. Momentum 92.5 / Value 41.1 / Sentiment 26.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.97B
Beta
0.98
Shares Out
68.56M
P/E (TTM) · Derived
-36.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-37.73
Rev YoY
-
EPS YoY
+64.1%
Gross Margin
-
Op Margin
-
Net Debt
-$280.2M
Current Ratio
23.04
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology